SEC Tracker
Get the app

Neurocrine Biosciences NBIX

Eiry Roberts reports stock option and RSU grant

Eiry Roberts (Chief Medical Officer) reported option or other derivative trades in NBIX

Form
4
Filed
Importance
Routine
  1. Stock option for 8,314 shares at $166.05
  2. Restricted Stock Units (shares paid out over time) for 1,506 shares
  3. RSUs to settle annually from 2027 to 2030

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Neurocrine Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Exelixis EXEL public float $9.4B, Jul 4, 2025
  2. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
  3. BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.